Long-term follow-up in the PALLAS study showed no overall survival benefit with palbociclib plus endocrine therapy compared to endocrine therapy alone in hormone receptor-positive, HER2-negative ...

Pfizer's oral HER2 inhibitor Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive ...

A new Tufts study found that Medicare price negotiations on biologics with imminent biosimilars could lead to near-term savings, but greater savings are likely from biosimilar competition.

BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, ...

Roche RHHBY announced positive new data from a pre-specified interim analysis of its late-stage breast cancer study on ...

Abemaciclib monotherapy benefited 33% of patients with HR-positive, HER2-negative breast cancer post-CDK4/6 inhibitor progression. Abemaciclib shows promise as a monotherapy for HR-positive, ...

Resistance to initial therapy sets the stage for many other options ...

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...

Novel weapons to counter endocrine therapy resistance and treat progressive disease ...

The trial results support Tukysa-Herceptin-Perjeta as yet another option for breast cancer patients in the frontline ...

Data presented at ASH suggested that CDK4/6 inhibitors given with chemo for Rb-deficient tumors could mitigate the risk of secondary myeloid neoplasms.